Myriad Genetics Inc Dossier
Qualitative Analysis
Business overview
Myriad Genetics, Inc. (NASDAQ: MYGN) is a leading molecular diagnostics and precision medicine company. The company develops and commercializes genetic tests designed to assess the risk of developing disease, evaluate disease progression, and guide treatment decisions across multiple medical specialties. Its core product portfolio is organized around three primary clinical areas: Oncology (including the Prolaris prostate cancer test, myRisk Hereditary Cancer test, and MyChoice CDx companion diagnostic), Mental Health (featuring the GeneSight pharmacogenomic test), and Women's Health (including the Foresight carrier screen and Prequel prenatal screen). Myriad operates high-throughput laboratories in Salt Lake City, Utah, and Mason, Ohio, utilizing advanced robotics and data analytics to deliver genetic insights.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing on expanding the oncology portfolio through key product launches, including the Precise MRD platform, the AI-enabled Prolaris test, and the expanded MyRisk hereditary cancer panel.
Expected impact: Aims to accelerate annual revenue growth to high-single-digit to low-double-digit percentages over the mid- to long-term.
Implementing organizational structure changes, real estate optimization, and disciplined cost management to reduce operating expenses as a percentage of revenue.
Expected impact: Aims to support margin expansion and improve profitability, targeting positive adjusted EBITDA and long-term operating leverage.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of a developer of fetal development diagnostic genetic tests (including SneakPeek) to expand Myriad's portfolio in the prenatal and women's health space.
Financial impact: Contributed to prenatal testing volumes, though the segment experienced transition dynamics and uneven performance through 2025.
Strategic Partnerships
To develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test, leveraging Myriad's advanced laboratory capabilities in the US and SOPHiA's decentralized global network.
Terms: Both companies will collaborate across development activities, with Myriad pursuing US regulatory submissions and SOPHiA managing submissions outside the US.
To develop and commercially launch Myriad's first AI-enabled prostate cancer prognostic test, combining Prolaris with PATHOMIQ's AI-powered digital pathology technology.
Terms: Not explicitly disclosed
Launched the first integrated AI and genetic risk platform for personalized breast health, enhancing Myriad's leadership in precision breast health and risk assessment.
Terms: Not explicitly disclosed